GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » EBITDA Margin %

Telix Pharmaceuticals (Telix Pharmaceuticals) EBITDA Margin % : 9.43% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Telix Pharmaceuticals's EBITDA for the six months ended in Dec. 2023 was $17.6 Mil. Telix Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $186.3 Mil. Therefore, Telix Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2023 was 9.43%.


Telix Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Telix Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals EBITDA Margin % Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -702.42 -894.86 -1,430.48 -55.66 4.62

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,510.44 -287.72 -16.52 -1.51 9.43

Competitive Comparison of Telix Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Telix Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's EBITDA Margin % falls into.



Telix Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Telix Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=15.372/332.436
=4.62 %

Telix Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=17.574/186.311
=9.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (OTCPK:TLPPF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Telix Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.